{"id":35212,"date":"2024-02-07T16:10:24","date_gmt":"2024-02-07T10:40:24","guid":{"rendered":"https:\/\/businesspoint.co.in\/index.php\/2024\/02\/07\/vaishali-pharmas-q3-fy24-marked-by-a-remarkable-37-59-increase-in-revenue\/"},"modified":"2024-02-07T16:10:24","modified_gmt":"2024-02-07T10:40:24","slug":"vaishali-pharmas-q3-fy24-marked-by-a-remarkable-37-59-increase-in-revenue","status":"publish","type":"post","link":"https:\/\/businesspoint.co.in\/index.php\/2024\/02\/07\/vaishali-pharmas-q3-fy24-marked-by-a-remarkable-37-59-increase-in-revenue\/","title":{"rendered":"Vaishali Pharma\u2019s Q3 FY24 marked by a remarkable 37.59% increase in revenue"},"content":{"rendered":"
\n

Mumbai (Maharashtra) [India], February 7: Vaishali Pharma Limited (NSE \u2013 VAISHALI), engaged in production and marketing of a diverse range of pharmaceutical products, announced its unaudited Financial Results for Q3 & 9M FY24.<\/p>\n

Key Financials at a Glance:\u00a0<\/strong><\/p>\n

Q3 FY24<\/strong><\/p>\n

\u2013 Total Income at\u00a0\u20b9\u00a028.37 Cr<\/p>\n

\u2013 EBITDA at\u00a0\u20b9\u00a03.42 Cr<\/p>\n

\u2013 EBITDA Margin at 12.05%<\/p>\n

\u2013 Net Profit at\u00a0\u20b9\u00a02.11 Cr<\/p>\n

\u2013 NPM (%) at 7.44%<\/p>\n

\u2013 EPS at\u00a0\u20b9\u00a01.99<\/p>\n

9M FY24<\/strong><\/p>\n

\u2013 Total Income at\u00a0\u20b9\u00a055.01 Cr<\/p>\n

\u2013 EBITDA at\u00a0\u20b9\u00a09.05 Cr<\/p>\n

\u2013 EBITDA Margin at 16.45%<\/p>\n

\u2013 Net Profit at\u00a0\u20b9\u00a05.4 Cr<\/p>\n

\u2013 NPM (%) at 9.82%<\/p>\n

\u2013 EPS at\u00a0\u20b9\u00a05.10<\/p>\n

Commenting on the performance, Atul Vasani, Chairman and Managing Director of\u00a0Vaishali Pharma Limited said,\u00a0\u201cWe are delighted to share our Q3 FY24 results, reflecting our steadfast commitment to innovation, high-quality standards, and strategic global expansion through valuable partnerships. Notably, we introduced our latest brand, \u201cHealthE,\u201d through an online platform, showcasing our dedication to providing health and wellness solutions that enhance lives. Additionally, our participation in CPHI Barcelona (Spain) underscores our active engagement in the global market.\u00a0Our ongoing collaborations and strategic ventures, including the Nutraceutical Products segment, position us for future growth.<\/p>\n

We look forward to advancing our journey towards excellence, prioritizing stakeholder value and contributing significantly to global healthcare improvement.\u201d<\/p>\n

\n\n\n\n\n\n
Highlights for Q3 FY24 (October 2023 \u2013 December 2023)<\/td>\n<\/tr>\n
\u00a0 \u00a0 The company exhibited at CPHI Barcelona (Spain).<\/td>\nCPHI Worldwide is one of the most comprehensive and recognized pharmaceutical exhibitions in the world. The exhibition is divided into six distinct zones, each representing a specific stage of the pharmaceutical supply chain. From APIs and machinery display to outsourcing and biopharmaceuticals, CPHI Worldwide provides a holistic approach to expanding the healthcare industry.<\/td>\n<\/tr>\n
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Introduced brand \u201cHEALTHE\u201d with the online platform<\/td>\nUnveiled its latest brand, \u201cHealthE.\u201d This significant development underscores the company\u2019s ongoing dedication to providing health and wellness solutions that enhance lives and foster enduring well-being. \u00a0 Central to this introduction is the launch of \u201cHealthE Biotin and Multivitamin Gummies,\u201d a groundbreaking product crafted to improve hair, skin, and overall health. These delightful gummies synergize the potency of biotin, vital vitamins, and natural extracts, fostering hair growth, enhancing skin radiance, and elevating overall vitality.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>
Vaishali Pharma\u2019s Q3 FY24 marked by a remarkable 37.59% increase in revenue<\/figcaption><\/figure>\n

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Mumbai (Maharashtra) [India], February 7: Vaishali Pharma Limited (NSE \u2013 […]<\/p>\n","protected":false},"author":1,"featured_media":35213,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[2],"class_list":["post-35212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-business"],"_links":{"self":[{"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/posts\/35212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/comments?post=35212"}],"version-history":[{"count":0,"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/posts\/35212\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/media\/35213"}],"wp:attachment":[{"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/media?parent=35212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/categories?post=35212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/businesspoint.co.in\/index.php\/wp-json\/wp\/v2\/tags?post=35212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}